Clinical trial
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol
NCT03290287 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 1, 2017
- Completion date
- June 30, 2022
- Enrollment
- 26,839 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.